Evidence map›Paper›PMID 23160370›Full record

ArticleOncogene2013

The neural guidance receptor Plexin C1 delays melanoma progression.

Y Chen, J Soong, S Mohanty, L Xu, G Scott

Abstract read
In one paragraph

Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Observational
  3. Review
  4. SEMAPHORINS and their receptors: focus on the crosstalk between melanoma and hypoxia.Journal of experimental & clinical cancer research : CR · 2021
    Review
  5. Article
  6. Article
  7. Article
  8. Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
  9. Review
  10. Article
  11. Article
  12. Gas5 Exerts Tumor-suppressive Functions in Human Glioma Cells by Targeting miR-222.Molecular therapy : the journal of the American Society of Gene Therapy · 2015
    Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Y ChenDepartment of Dermatology, University of Rochester School of Medicine, Rochester, NY, USA.
J Soong
S Mohanty
L Xu
G Scott
University of Rochester · US

Funding

TRAINING PROGRAM IN DERMATOLOGICAL RESEARCHT32AR007472 · NIAMS · UNIVERSITY OF ROCHESTER · PI PENTLAND, ALICE P · 1987 to 2013
$2.1M
Plexin signalling in melanocyte biology and melanoma progressionR01CA136499 · NCI · UNIVERSITY OF ROCHESTER · PI SCOTT, GLYNIS A · 2009 to 2013
$1.5M
NCI NIH HHS R01 CA136499NCI NIH HHS R01CA136499NIAMS NIH HHS 5T32AR007472NIAMS NIH HHS T32 AR007472
6 · The paper itself

Abstract

Plexin C1 is a type I transmembrane receptor with intrinsic R-Ras GTPase activity, which regulates cytoskeletal remodeling and adhesion in normal human melanocytes. Melanocytes are pigment-producing cells of the epidermis, precursors for melanoma, and express high levels of Plexin C1, which is lost in melanoma in vitro and in vivo. To determine if Plexin C1 is a tumor suppressor for melanoma, we introduced Plexin C1 into a primary human melanoma cell line, and phenotypes including migration, apoptosis, proliferation and tumor growth in mice were analyzed. Complimentary studies in which Plexin C1 was silenced in human melanocytes were performed. Plexin C1 significantly inhibited migration and proliferation in melanoma, whereas in melanocytes, loss of Plexin C1 increased migration and proliferation. In mouse xenografts, Plexin C1 delayed tumor growth of melanoma at early time points, but tumors eventually escaped the suppressive effects of Plexin C1, due to Plexin C1-dependent activation of the pro-survival protein Akt. R-Ras activation stimulates melanoma migration. Plexin C1 lowered R-Ras activity in melanoma and melanocytes, consistent with inhibitory effects of Plexin C1 on migration of melanocytes and melanoma. To determine if R-Ras is expressed in melanocytic lesions in vivo, staining of tissue microarrays of nevi and melanoma were performed. R-Ras expression was highly limited in melanocytic lesions, being essentially confined to primary melanoma, and almost completely absent in nevi and metastatic melanoma. These data suggest that loss of Plexin C1 in melanoma may promote early steps in melanoma progression through suppression of migration and proliferation, but pro-survival effects of Plexin C1 ultimately abrogate the tumor suppressive effects of Plexin C1. In primary melanoma, loss of Plexin C1 may function in early steps of melanoma progression by releasing inhibition of R-Ras activation, and stimulating migration.

Indexed as

Disease ProgressionAnimalsApoptosisCarcinogenesisCell Line, TumorCell MovementCell ProliferationEnzyme ActivationHumansMelanocytesMelanomaMiceras ProteinsReceptors, VirusShelterin ComplexTelomere-Binding Proteinsras ProteinsReceptors, VirusRRAS protein, humanShelterin ComplexTelomere-Binding ProteinsTERF2IP protein, humanTumor Suppressor ProteinsVESPR semaphorin receptor

Identifiers

PMID23160370
PMCPMC3758461
OpenAlexW1984551026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.